SOURCES SOUGHT
66 -- Axiom Genome Wide YRI Genotyping Bundle
- Notice Date
- 7/13/2011
- Notice Type
- Sources Sought
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- NHLBI-CSB-(HG)-2011-253-DLM
- Archive Date
- 8/6/2011
- Point of Contact
- Dorothy Maxwell, Phone: 301-435-0352
- E-Mail Address
-
maxwelld@mail.nih.gov
(maxwelld@mail.nih.gov)
- Small Business Set-Aside
- Total Small Business
- Description
- This Sources Sought Notice (SS) is for information and planning purposes only and shall not be construed as a solicitation or as an obligation on the part of the National Heart, Lung, and Blood Institute (NHLBI). The purpose of this SS is to identify qualified small business concerns [including Small Disadvantaged Businesses (SDB), Woman-owned Small Businesses (WOSB), Historically Underutilized Business Zone (HUBZone) Small Businesses, Veteran-Owned Small Businesses (VOSB) and Service-Disabled Veteran-owned Small Businesses (SDVOSB] that are interested in and capable of providing the below: Axiom Genome Wide YRI Genotyping Bundle (Must be compatible with Affymetrix GeneTitan MC Instrument). The NHLBI does not intend to award a contract on the basis of responses nor otherwise pay for the preparation of any information submitted. As a result of this Sources Sought notice, the NHLBI may issue a Request for Quote (RFQ). THERE IS NO SOLICITATION AVAILABLE AT THIS TIME. However, should such a requirement materialize, no basis for claims against NHLBI shall arise as a result of a response to this Sources Sought notice or the NHLBI's use of such information as either part of our evaluation process or in developing specifications for any subsequent requirement. The NHLBI is seeking capability statements from all eligible small business concerns [particularly Small Disadvantaged Businesses (SDB), Woman-owned Small Businesses (WOSB), Historically Underutilized Business Zone (HUBZone) Small Businesses, Veteran-Owned Small Businesses (VOSB) and Service-Disabled Veteran-owned Small Businesses (SDVOSB)] under the North American Industry Classification System (NAICS) code 334516 with a size standard 500 employees. Based on the responses received from this SOURCES SOUGHT announcement, the proposed acquisition may be solicited as a Total Small Business Set-Aside. All eligible small business concerns responding to this Sources Sought Announcement must have the capabilities to provide services as below. Product : 1. Axiom Genome Wide YRI Genotyping Bundle, Item Number: 901788, Quantity: Nineteen (19) Each. (Must be compatible with Affymetrix GeneTitan MC Instrument). 2. Samples Genotyped on the Axiom YRI Panel, Quantity: 1,824 Samples. Background : The mission of the Center for Research on Genomics and Global Health (CRGGH), National Human Genome Research Institute (NHGRI), National Institute of Health (NIH) is to advance research into the role of culture, lifestyle, genetics and genomics in disease etiology, differential susceptibility to disease and variable drug response at the individual and population levels. As part of this mission, the center has been collecting and analyzing samples from different parts of the world such as Africa, China and the United States to study the genetics of complex and common diseases in different populations. CRGGH's lab has ongoing large-scale genetic epidemiology studies of type 2 diabetes (T2D) in Africans. The Africa America Diabetes Mellitus (AADM) Study, as part of these studies his lab has accumulated over 2,000 DNA samples from his international collaborators in Africa to conducted genomic studies into the genetic basis of T2D with the ultimate of informing the health disparity observed in African Americans compared to their European counterparts. The purpose of the Africa America Diabetes Mellitus (AADM) study is to identify genetic variants associated with T2D and related traits in African populations through an international collaboration between African and US investigators. We chose to study T2D in African populations, where diabetes is less common than in the US, reasoning that in an environment where calories are less abundant, incidence cases of T2D might carry a proportionately greater genetic component providing a novel and highly productive subject population for genetic and epidemiological studies of T2D. The Axiom Genome Wide YRI Genotyping Bundle will be used for the following : • Genotype 1200 cases of T2D and 624 controls enrolled in the Africa America Diabetes Mellitus (AADM) study using the newly design and optimized for African populations. • Genotyping of the 1,824 subjects will be conducted in the lab of The Center for Applied Genomics, Children's Hospital of Philadelphia (CHOP) using the Affymetrix YRI Axiom panel. • Conduct a genome-wide association study (GWAS) of T2D and related traits on completed genotypes adjusting for important covariates including age, sex and BMI. The AxiomTM Genome-Wide YRI Genotyping Bundle is composed of Axiom Genome-Wide YRI Array plates, Axiom 2.0 Reagent Kits and GeneTitan.® The AxiomTM Genome-Wide YRI Array Set: includes arrays, reagents, and analysis software, is part of the AxiomTM Genotyping Solution. This innovative technology for genotyping studies includes predesigned and customized array plates with validated genomic content from the AxiomTM Genomic Database of 11M validated SNPs, as well as complete reagent kits, data analysis tools, and a fully automated workflow utilizing the GeneTitan® Multi-Channel (MC) Instrument. Axiom Genome-Wide Arrays are a family of predesigned, population-optimized panels that offer optimal coverage for genome-wide association, replication, and candidate gene association studies. 1. Highest Genetic Coverage of the Yoruba Genome: a. The only commercially available genotyping array set that offers ~90% genome-wide coverage in the Yoruba genome. b. The only genotyping array set optimized to tag YRI haplotypes, including singletons. c. The only array set that offers >89.0% coverage of rare variantsin the YRI genome. d. The only array set that simultaneously offers >86% coverage in the YRI genome in all major biological categories, including cardiovascular genes, drug etabolism genes, major histocompatibilty complex (MHC), inflammatory/immunity pathway, Sanger Cancer Census and the NHGRI Catalog of Published Genome-Wide Associations. e. The only commercially available genotyping array set that offer consistent coverage across all 21 autosomal chromosomes. 2. The AxiomTM Genome-Wide YRI Array Set provides the highest genetic coverage of admixed African American genome: a. The only commercially available array set that offers ~87% genome-wide coverage of an African American genome (ASW), an admixed population based on western African and European ancestry. 3. The only YRI optimized array set that is build on the most complete YRI genome "build": a. that is constructed from HapMap, 1000 Genomes (all 3 pilot projects) and dbSNP; and b. the only commercially available array set with genetic content discovered in the Southern African Genomes Project. 4. The only commercially available array set designed with biologically and analytically validated YRI variants from the AxiomTM Genomic Database. a. The only array set validated against 630 HapMap samples, including the following: o 180 YRI HapMap samples; o 90 ASW HapMap samples; o 90 MKK HapMap samples; o 90 LWK HapMap samples; o 90 CEU HapMap samples; and o 90 JPT + CHB HapMap samples. Interested qualified small business organizations should submit a tailored capability statement for this requirement, not to exceed 20 single-sided pages (including all attachments, resumes, charts, etc.) presented in single-space and using a 12-point font size minimum, that clearly details the ability to perform the aspects of the notice described above and in the draft SOW. All proprietary information should be marked as such. Statements should also include an indication of current certified small business status; this indication should be clearly marked on the first page of your capability statement (preferably placed under the eligible small business concern's name and address). Responses will be reviewed only by NIH personnel and will be held in a confidential manner. All capability Statements sent in response to this SOURCES SOUGHT notice must be submitted electronically (via email) to Dorothy Maxwell, Contract Specialist, at maxwelld@mail.nih.gov in either MS Word or Adobe Portable Document Format (PDF), by July 22, 2011 7:30 AM, EST. All responses must be received by the specified due date and time in order to be considered.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/NHLBI-CSB-(HG)-2011-253-DLM/listing.html)
- Place of Performance
- Address: NIH/NHGRI Center for Applied Genomics/Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Record
- SN02497303-W 20110715/110713234924-cbc7982bb1ed00f07b6ecaf384b6283c (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |